Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jonathan Daniel Schoenfeld, M.D.

Co-Author

This page shows the publications co-authored by Jonathan Schoenfeld and Frank Hodi.
Connection Strength

3.746
  1. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2022 02; 23(2):279-291.
    View in: PubMed
    Score: 0.981
  2. Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features. J Immunother Cancer. 2019 04 24; 7(1):112.
    View in: PubMed
    Score: 0.812
  3. Correction: A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2021 Sep 01; 27(17):4940.
    View in: PubMed
    Score: 0.239
  4. A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2021 05 01; 27(9):2470-2480.
    View in: PubMed
    Score: 0.230
  5. The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors. Int J Radiat Oncol Biol Phys. 2019 01 01; 103(1):142-151.
    View in: PubMed
    Score: 0.195
  6. Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation. Radiother Oncol. 2017 07; 124(1):98-103.
    View in: PubMed
    Score: 0.179
  7. Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy. Int J Radiat Oncol Biol Phys. 2017 06 01; 98(2):344-351.
    View in: PubMed
    Score: 0.174
  8. Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. Br J Cancer. 2016 07 12; 115(2):252-60.
    View in: PubMed
    Score: 0.167
  9. Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients. J Immunother Cancer. 2016; 4:32.
    View in: PubMed
    Score: 0.167
  10. Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes. Cancer Immunol Res. 2016 08; 4(8):679-87.
    View in: PubMed
    Score: 0.167
  11. A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology. 2015 Nov; 4(11):e1046028.
    View in: PubMed
    Score: 0.155
  12. Active immunotherapy induces antibody responses that target tumor angiogenesis. Cancer Res. 2010 Dec 15; 70(24):10150-60.
    View in: PubMed
    Score: 0.114
  13. Long-term Overall Survival and Predictors in Anti-PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study. J Immunother. 2021 10 01; 44(8):307-318.
    View in: PubMed
    Score: 0.060
  14. Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non-small cell lung cancer and melanoma brain metastases. Cancer. 2020 12 15; 126(24):5274-5282.
    View in: PubMed
    Score: 0.056
  15. Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition. J Immunother Cancer. 2019 03 29; 7(1):89.
    View in: PubMed
    Score: 0.051
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.